
Last Price
52 Week Range
SGD11.30 - SGD17.33
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | SGD3.42B |
EV | SGD2.67B |
Shares Outstanding | 221.37M |
Beta | 0.21 |
Industry | Drug Manufacturers - General |
Analyst Rating | - |
Analyst Target Price | - |
Number of Analysts | 0 |
P/E 2026E | 12.75x |
P/Revenue 2026E | 15.37x |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2026E | - |
Net Profit Margin 2026E | 112.85% |
ROE 2026E | 5.90% |
ROCE 2025 | 6.29% |
DPS 2026E | SGD0.45 |
Payout Ratio 2026E | 36.00% |
Div. Yield 2026E | 2.69% |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y

Haw Par Corporation Limited
H02
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Wee, Ee Lim
Employees
595
Website
www.hawpar.comIPO Date
2000-01-03
Headquarters
No. 03-03 Haw Par Technocentre, 401 Commonwealth Drive, Singapore 149598, Singapore
The last closing price of Haw Par Corporation (H02) is SGD16.77, reflecting a -1.30% change from the prior session. Last updated: April 2, 2026 at 6:19 AM Eastern Time
Review of Recent H02 Stock Performance trends:Past 1 Month: Haw Par Corporation (H02) shares changed by -7.71%.Past 3 Months: The stock recorded a change of -1.09%.Past 6 Months: H02 shares posted a change of +8.12%. Last updated: March 7, 2026 at 8:53 PM Eastern Time
Over the last year, Haw Par Corporation (H02) has established a 52-week price range between a high of SGD17.33 and a low of SGD11.30. This metric is essential for assessing the stock's annual volatility. Last updated: March 7, 2026 at 8:53 PM Eastern Time
Haw Par Corporation (H02) is considered a low volatility stock. It has a beta of 0.21, which means it typically moves 0.21 times as much as the broader market. Over the past 52 weeks, H02 has traded within a SGD11.30 – SGD17.33 range. Last updated: March 7, 2026 at 8:53 PM Eastern Time
A SGD1,000 investment in Haw Par Corporation 5 years ago, when the stock was trading around SGD13.52, would be worth approximately SGD1240.23 today, based solely on share price performance (excluding dividends). This represents a total return of 24.02% over the period, equivalent to a compound annual growth rate (CAGR) of 4.40%. Past performance reflects historical price movements only and does not imply future results. Last updated: March 7, 2026 at 8:53 PM Eastern Time
The current Haw Par Corporation (H02) market capitalization is approximately SGD3.42B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Haw Par Corporation's market cap fluctuates with changes in its share price and share count. Last updated: March 7, 2026 at 8:53 PM Eastern Time
In the most recently reported quarter, Haw Par Corporation (H02) generated SGD51.81M in revenue, representing a -18.22% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: April 2, 2026 at 4:08 AM Eastern Time
In the most recently reported fiscal year, Haw Par Corporation (H02) generated net income of SGD265.46M, compared with SGD228.27M in the prior fiscal year, representing a +16.29% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of SGD276.12M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: April 2, 2026 at 4:08 AM Eastern Time
According to its latest quarterly filing, Haw Par Corporation (H02) reported EBITDA of SGD18.51M, representing a +4.54% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: April 2, 2026 at 4:08 AM Eastern Time
As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.01x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: April 2, 2026 at 4:08 AM Eastern Time
Based on the latest available data, Haw Par Corporation (H02) is currently trading at a last twelve months (LTM) P/E ratio of 13.99x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: April 2, 2026 at 6:19 AM Eastern Time
In the most recently reported quarter, Haw Par Corporation (H02) revenue was SGD51.81M. Earnings per share (EPS) for the quarter were SGD0.27. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: April 2, 2026 at 4:08 AM Eastern Time
Based on the latest available analyst coverage, Haw Par Corporation (H02) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: April 2, 2026 at 6:19 AM Eastern Time
Like other publicly traded stocks, Haw Par Corporation (H02) shares are bought and sold on stock exchanges such as SGX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Haw Par Corporation (H02) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add H02 to your watchlist.
Haw Par Corporation trades under the ticker symbol H02 on the SGX stock exchange. The ticker H02 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
As of the most recently reported period, Haw Par Corporation (H02) employs approximately 595 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: March 7, 2026 at 8:53 PM Eastern Time
Haw Par Corporation (H02) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Haw Par Corporation (H02) stock peers based on overlapping products, services, and competitive dynamics:AFT Pharmaceuticals (AFT)Hyphens Pharma International (1J5)Whan In Pharm (A016580)Nxera Pharma (4565)Shanghai Kaibao Pharmaceutical (300039)GlaxoSmithKline Pakistan (GLAXO)Theragen Etex (A066700)JW Lifescience (A234080)Lee's Pharmaceutical Holdings (950)Egyptian International Pharmaceutical Industries (PHAR) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Haw Par Corporation.
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data Providers